Skip to content
OpenCapital
Get started

LivaNova LIVN Cash & Equivalents

Cash & Equivalents at other companies

Abbott logo
AbbottABT
$6.8B+4.1%
Haemonetics logo
HaemoneticsHAE
$245.44M-20.0%
Medtronic logo
MedtronicMDT
$1.95B-12.1%
ResMed logo
ResMedRMD
$1.66B+78.0%
Boston Scientific logo
Boston ScientificBSX
$850M+146%
Stryker logo
StrykerSYK
$2.88B+24.1%

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.31B+62.8%
Enterprise value$4.11B+58.0%
P/S3×+0.9×

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's cash & equivalents?
LivaNova (LIVN) reported cash & equivalents of $539.71M in Q1 2026.
How has LivaNova's cash & equivalents changed year-over-year?
LivaNova's cash & equivalents decreased by 26.9% year-over-year, from $738.44M to $539.71M.
What is the long-term trend for LivaNova's cash & equivalents?
Over 5 years (2020 to 2025), LivaNova's cash & equivalents has grown at a 20.2% compound annual growth rate (CAGR), from $252.83M to $635.55M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.